Understanding the New Breakthroughs in Weight Loss and Diabetes Care 

The mounting popularity of GLP-1 therapies is changing how people - and the healthcare system - address type 2 diabetes and obesity care. This distinguished panel of clinical leaders will share what they believe must be contemplated when healthcare leaders are making precise benefit decisions, despite having no historical parallel to the situation we currently face with GLP-1s.
Speakers:
Shealynn Buck, MD - Chief Medical Officer, Lockton
Robert Gabbay, MD, PhD, FACP - Chief Scientific and Medical Officer, American Diabetes Association
Timothy Law, DO, MBA - Chief Medical Officer, Highmark Health
Vidya Raman-Tangella - Chief Medical Officer, Teladoc Health